eHealth (EHTH) Q4 2025 earnings review
A Record Q4 Masked by a Brutal 2026 Contraction
eHealth delivered a strong finish to 2025, expanding Medicare unit economics and driving Adjusted EBITDA up 40% for the full year. By actively purging low-quality, third-party leads, the LTV-to-CAC ratio improved to 2.2x. However, the victory lap abruptly ends when looking forward. FY26 guidance reveals a massive structural reset, with revenue guided down ~23% and Adjusted EBITDA collapsing ~33% year-over-year. Management frames this contraction as an intentional optimization for cash flow and enrollment quality. While structurally sound for long-term health, shedding over $100 million in top-line revenue exposes how much empty volume previously propped up the business. The sheer magnitude of the near-term cliff poses severe execution risks.
🐂 Bull Case
Q4 Medicare LTV grew 11% to $1,304, while total acquisition costs were nearly flat (+1%). The deliberate pivot to branded, direct channels is yielding higher quality, longer-retaining members.
Despite shrinking the top line dramatically, the company expects to reach near break-even operating cash flow in 2026, pivoting away from cash-burning, volume-chasing strategies.
🐻 Bear Case
FY26 revenue is guided to reverse violently, dropping 23% at the midpoint. This implies massive volume losses as the company stops buying growth via third-party channels.
The broader MA market is deteriorating due to elevated utilization and fierce competition. Carriers are consolidating broker relationships, creating severe macro headwinds.
⚖️ Verdict: 🔴
Bearish. Improving unit economics is highly commendable, but intentionally shrinking the business by a quarter of its revenue signals severe underlying market pressure. The 2026 guidance is a hard pill to swallow.
Key Themes
The 'Cash Flow' Narrative Contradiction
Management claims the FY26 revenue cut is designed to 'optimize for cash flow' and drive profitability. However, the data contradicts this rosy narrative. While they are slashing ~$129M in revenue (midpoint), Adjusted EBITDA is simultaneously reversing by $32M (down 33%), and operating cash flow is only guided to improve to roughly break-even ($1M midpoint). This indicates the volume being shed was contributing meaningful scale, and fixed costs remain a heavy burden.
Unit Economics Tell a Winning Story
While volume shrank, quality spiked. Q4 Medicare Advantage constrained LTV grew 11% year-over-year to $1,304. At the same time, customer care and variable marketing costs were strictly managed, resulting in a total acquisition cost increase of just 1%. Consequently, the LTV-to-CAC ratio accelerated to 2.2x (up from 2.0x in 24Q4). The strategic shift away from low-intent, third-party leads is working.
AI Voice Agent Scales Efficiently
eHealth successfully shifted from piloting AI voice agents in Q2 to scaling them aggressively during the crucial Medicare Annual Enrollment Period (AEP). This technology handles high-volume initial call screening, drastically improving answer rates and routing efficiency, which helped hold Customer Care & Enrollment (CC&E) costs flat year-over-year for the full year.
Aggressive Cost Restructuring
To cushion the blow of the 2026 revenue drop, management initiated major cost-saving efforts starting in January 2026. The company targets $30 million in fixed cost savings and over $60 million in planned variable spend reductions. Execution on these cuts will be the sole mechanism preventing a deeper earnings collapse next year.
Macro: The Medicare Advantage Reset
The industry backdrop is brutal. Management highlighted elevated utilization trends, medical cost inflation, and heavy regulatory changes. Carriers are fiercely protecting their own margins by cutting benefit offerings and severing ties with low-quality brokers. This macro environment severely caps eHealth's organic growth potential and forces the current defensive posture.
Employer and Individual (E&I) Segment Lags Dramatically
The legacy E&I segment is in a severe, decelerating spiral. Q4 revenue collapsed 29% to $6.7M, and segment gross profit plunged 50% year-over-year. For the full year, E&I revenue dropped 28%. The company is essentially operating as a pure-play Medicare business, with its diversification arm failing to provide any structural support.
DOJ False Claims Act Litigation Overhang
A lingering shadow remains from the May 2025 complaint filed by the U.S. Attorney's Office alleging violations of the Federal False Claims Act. While the financial impact is unquantified in the current release, the legal distraction and potential reputational damage with critical carrier partners remains a severe risk factor.
Other KPIs
Accelerating. The total balance grew 12% year-over-year, representing the company's core asset. The short-term portion ($236.1M) gives management a healthy immediate cash collection pipeline, giving them the flexibility to transition to their 2026 cash-flow optimization strategy.
Accelerating. Grew 12% YoY, outpacing the segment's 5% revenue growth. This demonstrates high operating leverage during the core AEP period and proves that shedding low-quality volume materially improves gross margin percentages.
Guidance
Reversing. The midpoint of $425 million implies a brutal 23% year-over-year contraction, erasing the 4% growth achieved in FY25. This reflects the deliberate abandonment of low-margin third-party channels and broader Medicare market headwinds.
Reversing. Decelerating sharply from the $97.3 million delivered in FY25. The implied 33% decline demonstrates that despite management's targeted $90 million in cost cuts, the loss of scale and volume will severely damage absolute profitability.
Decelerating. A steep drop from FY25's $40.0 million. While the company will remain technically profitable on a GAAP basis, the margin compression is severe.
Accelerating. A massive improvement from FY25's $(25.3) million cash burn. This is the sole bright spot in the guidance, reflecting a structurally changed business model that no longer pays out excessive upfront customer acquisition costs for low-retention members.
Key Questions
EBITDA Leverage Disconnect
If the volume being shed in 2026 is truly low-margin, third-party business, why is Adjusted EBITDA guided to contract by 33%, a steeper rate than the 23% revenue decline? This implies the shed volume was carrying significant fixed-cost absorption.
Cost Savings Execution
You outlined $30 million in fixed and $60 million in variable cost savings planned for 2026. What portion of these cuts is already secured, and are there further levers to pull if AEP volumes fall below your newly lowered expectations?
Carrier Partner Sentiment
With carriers aggressively consolidating broker relationships to protect their own margins, how has eHealth's carrier compensation and SLA structure been altered heading into 2026?
E&I Segment Viability
Given the 28% annual decline in Employer and Individual segment revenue, is there a strategic argument for divesting or shutting down this segment entirely to focus purely on the Medicare transition?